The safety and efficacy of low-dosage tirofiban for stent-assisted coiling of ruptured intracranial aneurysms
- PDF / 395,156 Bytes
- 8 Pages / 595.276 x 790.866 pts Page_size
- 64 Downloads / 181 Views
ORIGINAL ARTICLE
The safety and efficacy of low-dosage tirofiban for stent-assisted coiling of ruptured intracranial aneurysms Yazhou Yan 1 & Xiaowu He 1 & Yibin Fang 1 & Yi Xu 1 & Bo Hong 1 & Jianmin Liu 1 & Qinghai Huang 1 Received: 1 June 2020 / Revised: 17 August 2020 / Accepted: 21 September 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Stent-assisted coiling (SAC) of acutely ruptured aneurysms with antiplatelet therapy has been controversial. Tirofiban has been used for the treatment of thromboembolism of ruptured aneurysms with a stent. However, there are few comparative studies of a reasonable dosage for the prophylactic use of tirofiban. This study evaluated the safety and efficacy of reducing the dosage of tirofiban for the ruptured aneurysms with SAC. Patients with ruptured intracranial aneurysms in our institution from January 2014 to June 2018 were retrospectively reviewed. Three hundred and nine patients were treated using SAC within 72 h of onset. Patients were divided into either a standard group (211 patients, 10 μg/kg intravenous bolus within 3 min, maintained with 0.15 μg/kg/min) or a half-dose group (98 patients, 5 μg/kg intravenous bolus within 3 min, maintained with 0.075 μg/kg/min) according to the dose of tirofiban received intraoperatively. Medical records including clinical and radiological details were reviewed. No significant differences in demographic information or aneurysm characteristics existed between the two groups. Thromboembolic complications were found in 15 patients (4.9%), including 11 patients (5.2%) in the standard group and four patients (4.1%) in the half-dose group, without significant difference (P = 0.782). Intracranial hemorrhage was found in 13 patients (4.2%), and all occurred in the standard group, which was significantly different (6.2% vs 0%, P = 0.011). Of these 13 patients, four were left disabled and five died. Except for three patients who had intraoperative aneurysm rupture, the incidence of postoperative early rebleeding (10 patients) was significantly different between the two groups (4.7% vs 0%, P = 0.034). The rate of initial complete occlusion in the half-dose group was significantly higher than that in the standard group (55.1% vs 39.8%). The rate of a good outcome (modified Rankin Scale 0–2) was not significantly different between the standard group and half-dose group (78.7% vs 87.8%, P > 0.05). Intravenous tirofiban for SAC of acutely ruptured intracranial aneurysms is feasible and safe. The half-dose tirofiban treatment was associated with a decrease in the prevalence of intracranial hemorrhage but no increase in thromboembolic events compared with those in standard-dose tirofiban treatment. Keywords Ruptured aneurysm . Subarachnoid hemorrhage . Stents . Tirofiban . Platelet aggregation inhibitors
Introduction The International Subarachnoid Aneurysm Trial suggested that endovascular treatment for intracranial aneurysm was an effective, safe, and sometimes preferable treatment protocol Yazhou Yan and Xiaowu He contrib
Data Loading...
